mipomersen

• “Genzyme is appealing because of its multiple sclerosis drug Campath, which could reach the market in 2012, plus a cholesterol lowering treatment, mipomersen, which is in late-stage clinical trials.”

  The Guardian: Genzyme rejects Sanofi-Aventis 'bear hug'

• “The drug from Isis, called mipomersen, is in late-stage clinical testing.”

  The Wall Street Journal: Genzyme Boosts Pipeline

• “SUNDAY, March 14 (HealthDay News) -- A new drug called mipomersen reduced low-density lipoprotein (LDL) "bad" cholesterol by nearly 25 percent when added to current therapy in people with a rare genetic condition that causes extremely high cholesterol, a new study finds.”

  Medlogs - Recent stories

• “Carlsbad, Calif., drug-development company Isis Pharmaceuticals and large-cap biotechnology company Genzyme, based in Cambridge, Mass., said data from a late-stage study of mipomersen, which treats a rare genetic disorder that elevates patients 'cholesterol levels and puts them at higher risk for heart problems, met its primary endpoint.”

  The Wall Street Journal: P 600 Snaps 10-Day Winning Streak

• “These are Campath for treating multiple sclerosis; mipomersen, in development with Isis Pharmaceuticals Inc. for a rare cholesterol-related disorder; and eliglustat, an oral treatment for Gaucher's disease.”

  The Wall Street Journal: Genzyme Plans Buyback, to Shed Businesses

• “In this case, Mr. Crooke, disappointed with the market response after releasing the Phase III results of mipomersen back in May, upped the volume by saying mipomersen represents the third “remarkable” drug he has developed.”

  The Effusive CEO « CXO Footnotes

• “Carlsbad, Calif. -based Isis Pharmaceuticals and large-cap Genzyme said their mipomersen drug cut bad cholesterol levels by 25% in a late-stage study of patients who have a rare genetic disorder.”

  The Wall Street Journal: AnnTaylor, Palm Fall; Tween Brands Soars

• “In January, Isis licensed mipomersen to Genzyme, which will develop and commercialize it.”

  The Wall Street Journal: Isis and Genzyme Must Prove

• “The companies initially plan to file for approval of mipomersen as a treatment for a rare genetic disease involving high cholesterol, known as homozygous familial hypercholesterolemia, or hoFH.”

  The Wall Street Journal: Isis and Genzyme Must Prove

• “The companies updated the timeline for regulatory submission of the drug, mipomersen, after receiving FDA guidance on what would be required before the agency could approve it.”

  The Wall Street Journal: Isis and Genzyme Must Prove

Show 10 more examples...